Per the terms of the emergency use authorization granted on May 1, the U.S. government is charged with dispensing the medication, though Gilead has also established supply agreements with other countries, and the drug has received full regulatory approval in markets like Japan under the name Veklury.The company cited lower PrEP demand as a result of the pandemic, “driven by reduced initiations and therapy discontinuations due to reduced [health care provider] visits and impact on social dynamics.” SVB Leerink’s Geoffrey Porges had told investors last week to expect sales of Gilead’s HIV prevention drugs “to be materially lower than prior periods given social distancing.” Gilead’s stock is up 10.9% since the start of the year, while the broader S&P 500